Phase II Trial of Sorafenib Combined With Concurrent Hepatic Arterial Infusion (HAI) of Oxaliplatin, 5-fluorouracil and Leucovorin for Hepatocellular Carcinoma
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 12 Mar 2017 Primary endpoint changed from Adverse Events to progression-free survival rate due to which trial focus has changed.
- 12 Mar 2017 Planned End Date changed from 1 Feb 2018 to 1 Apr 2017.
- 12 Mar 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Apr 2017.